TUSC2 and lung carcinoma: Deng and colleagues reported that forced expression of TUSC2 enhanced the antitumour activity of cisplatin in human lung cancer cells [9]; TUSC2 restoration sensitized lung cancer cells to treatment with EGFR inhibitors [10].